Neurogene (NASDAQ:NGNE) Releases Earnings Results, Misses Estimates By $0.11 EPS

Neurogene (NASDAQ:NGNE) released its quarterly earnings data on Tuesday. The company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.42) by ($0.11), FiscalAI reports.

Neurogene Trading Down 11.2%

NASDAQ NGNE traded down $4.11 during trading on Tuesday, hitting $32.44. The company had a trading volume of 34,951 shares, compared to its average volume of 183,172. Neurogene has a one year low of $15.93 and a one year high of $43.66. The company has a market cap of $512.60 million, a price-to-earnings ratio of -7.11 and a beta of 1.70. The company’s fifty day moving average is $33.34 and its 200-day moving average is $26.46.

Insider Buying and Selling

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,200 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $36.13, for a total value of $151,746.00. Following the completion of the sale, the chief financial officer directly owned 84,040 shares in the company, valued at $3,036,365.20. This trade represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 9,600 shares of company stock valued at $339,932 in the last ninety days. Company insiders own 11.68% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its position in shares of Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in Neurogene by 3.4% during the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock valued at $531,000 after buying an additional 1,008 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after buying an additional 1,059 shares during the period. Daiwa Securities Group Inc. purchased a new position in Neurogene during the fourth quarter valued at $66,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Neurogene by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 249,695 shares of the company’s stock valued at $5,145,000 after buying an additional 3,262 shares in the last quarter. Institutional investors own 52.37% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Guggenheim assumed coverage on Neurogene in a report on Tuesday, April 28th. They set a “buy” rating and a $69.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Neurogene in a research note on Tuesday, June 9th. Rodman & Renshaw initiated coverage on shares of Neurogene in a research report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a report on Friday, July 17th. Finally, UBS Group set a $70.00 price objective on shares of Neurogene in a research report on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $84.83.

Neurogene Company Profile

Neurogene, Inc is a clinical?stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno?associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9?based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.